Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.

AIM To develop novel nanoliposomes (Lip-ADR-Cer) codelivering doxorubicin (ADR) and PEGylated C16 ceramide (PEG-ceramide C16) to overcome multidrug resistance. MATERIALS & METHODS The antitumor activity and mechanism of Lip-ADR-Cer were evaluated. RESULTS & CONCLUSION The IC50 of Lip-ADR-Cer after 48-h treatment with the MCF-7/ADR and HL-60/ADR cancer cells, both being ADR resistant, was 2.2- and 1.4-fold effective respectively versus the general nanoliposomes with no PEG-ceramide C16 (Lip-ADR). The antitumor assay in mice bearing MCF-7/ADR or HL-60/ADR xenograft tumors confirmed the superior antitumor activity of Lip-ADR-Cer over Lip-ADR. We found that the improved therapeutic effect of Lip-ADR-Cer may be attributed to both of the cytotoxic effect of PEG-ceramide C16 and glucosylceramide synthase overexpression in multidrug resistance cells.

[1]  S. Simões,et al.  Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Ya-jun Guo,et al.  Polymer-lipid hybrid nanoparticles conjugated with anti-EGF receptor antibody for targeted drug delivery to hepatocellular carcinoma. , 2014, Nanomedicine.

[3]  Ya-jun Guo,et al.  Nanomedicine for treatment of cancer stem cells. , 2014, Nanomedicine.

[4]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[5]  W. V. van Cappellen,et al.  Improving Intracellular Doxorubicin Delivery Through Nanoliposomes Equipped with Selective Tumor Cell Membrane Permeabilizing Short-Chain Sphingolipids , 2013, Pharmaceutical Research.

[6]  Ya-jun Guo,et al.  Nanomedicine against multidrug resistance in cancer treatment. , 2012, Nanomedicine.

[7]  M. Kester,et al.  Development and use of ceramide nanoliposomes in cancer. , 2012, Methods in enzymology.

[8]  O. Terasaki,et al.  Evolution of packing parameters in the structural changes of silica mesoporous crystals: cage-type, 2D cylindrical, bicontinuous diamond and gyroid, and lamellar. , 2011, Journal of the American Chemical Society.

[9]  Y. Assaraf,et al.  Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  A. Eggermont,et al.  Enriching lipid nanovesicles with short‐chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. Feng,et al.  Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. , 2010, Journal of biomedical materials research. Part A.

[12]  B. Langlois,et al.  De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. , 2009, The international journal of biochemistry & cell biology.

[13]  Subra Suresh,et al.  Size‐Dependent Endocytosis of Nanoparticles , 2009, Advanced materials.

[14]  S. Feng,et al.  Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. , 2008, Biomaterials.

[15]  A. Giuliano,et al.  A role for ceramide in driving cancer cell resistance to doxorubicin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Y. Barenholz,et al.  Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[17]  Z. Duan,et al.  Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles , 2008, Clinical Cancer Research.

[18]  Tao L Lowe,et al.  Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. , 2008, Biomaterials.

[19]  Z. Duan,et al.  Paclitaxel and ceramide co‐administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer , 2007, International journal of cancer.

[20]  T. Trarbach,et al.  Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms , 2007, Apoptosis.

[21]  Z. Duan,et al.  Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. , 2007, Cancer research.

[22]  M Ferrari,et al.  The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. , 2007, Biomaterials.

[23]  Gert Storm,et al.  Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  T. Allen,et al.  Ligand-targeted liposomes for cancer treatment. , 2005, Current drug delivery.

[25]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[26]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[27]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[28]  M. Gottesman,et al.  Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. , 2004, Molecular cancer therapeutics.

[29]  T. Allen,et al.  Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes , 2004, Clinical Cancer Research.

[30]  M. Bally,et al.  In Vitro and in Vivo Characterization of Doxorubicin and Vincristine Coencapsulated within Liposomes through Use of Transition Metal Ion Complexation and pH Gradient Loading , 2004, Clinical Cancer Research.

[31]  M. Cabot,et al.  Targeting ceramide metabolism--a strategy for overcoming drug resistance. , 2001, Journal of the National Cancer Institute.

[32]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  A. Giuliano,et al.  Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. , 1999, International journal of oncology.

[34]  P. Cullis,et al.  Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties , 1999, Gene Therapy.

[35]  L. Palmer,et al.  Stabilized plasmid-lipid particles: construction and characterization , 1999, Gene Therapy.

[36]  A E Giuliano,et al.  Expression of Glucosylceramide Synthase, Converting Ceramide to Glucosylceramide, Confers Adriamycin Resistance in Human Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[37]  F. Goñi,et al.  Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. , 1999, Biophysical journal.

[38]  A E Giuliano,et al.  Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells* , 1996, The Journal of Biological Chemistry.

[39]  R. Macdonald,et al.  Effects of chain unsaturation on the equation of state for lipid monolayers at the air-water interface. , 1995, Biophysical journal.

[40]  V. V. Kumar,et al.  Complementary molecular shapes and additivity of the packing parameter of lipids. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J C Stewart,et al.  Colorimetric determination of phospholipids with ammonium ferrothiocyanate. , 1980, Analytical biochemistry.